Cannabis-Based Drug Could Treat Side Effects Of COVID-19

A Canadian startup called Akseera Pharma is working on a cannabis-based drug named Cannabidiol to treat patients suffering from cardiac damage as a side effect of COVID-19.

The pharmaceutical company is reportedly discussing with the government to carry out clinical trials. And if the drug is proved to be successful, Akseera Pharma plans to manufacture the drug in India.

Some states in the US and Canada have legalized the use of cannabis Cannabis is known to have psychoactive properties. But, at the same time, it carries with it several medicinal properties as well. And according to Akseera Pharma, it can cure arrhythmia.

Arrhythmia is a condition caused by improper heartbeat. Normally, our heart has a steady pace. But with arrhythmia, the heartbeat can accelerate or decelerate. This is mainly because of the heart’s electrical impulses not going in sync. If the condition is left unchecked, it can cause cardiac arrest or other severe heart conditions.

A recent study from Akseera has pointed out that the cannabis compound can rescue cardiac cells from being affected by arrhythmias. And based on this preclinical data, the company views it as a potential drug to deal with COVID-19 side effects.

As posted on the official website of the company, Akseera is testing Cannabidiol’s efficacy in Canada where it is legal to use cannabis for therapeutics since 2018.

Akseera also revealed that it was currently in discussion with the Drugs Controller General of India to start trials for CBD therapy in the country. The treatments could start at the end of 2020.

>>> Cannabis Sale Skyrockets After Study Shows It Can Prevent COVID-19 Infection